Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapy

Sun, Lulu; Shao, Qing

doi:10.1016/j.clinsp.2022.100135

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proteins such as CEA, NSE, CYFRA21-1, ProGRP, and SCCA serve as primary lung cancer biomarkers in clinical settings. NSE and ProGRP are principally employed for SCLC’s early diagnosis, efficacy monitoring, and prognostic assessment ( 18 - 20 ), while CEA, CYFRA21-1, and SCCA are predominantly used for NSCLC ( 21 - 23 ). CYFRA21-1 and SCCA hint at a higher likelihood of LUSC, and a close correlation exists between CEA and LUAD.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Yu,

Zheng,

Xia

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

Background Lung adenocarcinoma (LUAD), a global leading cause of cancer deaths, remains inadequately addressed by current protein biomarkers. Our study focuses on developing a protein-based risk signature for improved prognosis of LUAD. Methods We employed the least absolute shrinkage and selection operator (LASSO)-COX algorithm on The Cancer Genome Atlas database to construct a prognostic model incorporating six proteins (CD49B, UQCRC2, SMAD1, FOXM1, CD38, and KAP1). The model’s performance was assessed using principal component, Kaplan-Meier (KM), and receiver operating characteristic (ROC) analysis, indicating strong predictive capability. The model stratifies LUAD patients into distinct risk groups, with further analysis revealing its potential as an independent prognostic factor. Additionally, we developed a predictive nomogram integrating clinicopathologic factors, aimed at assisting clinicians in survival prediction. Gene set enrichment analysis (GSEA) and examination of the tumor immune microenvironment were conducted, highlighting metabolic pathways in high-risk genes and immune-related pathways in low-risk genes, indicating varied immunotherapy sensitivity. Validation through immunohistochemistry from the Human Protein Atlas (HPA) database and immunofluorescence staining of clinical samples was performed, particularly focusing on CD38 expression. Results Our six-protein model (CD49B, UQCRC2, SMAD1, FOXM1, CD38, KAP1) effectively categorized LUAD patients into high and low-risk groups, confirmed by principal component, KM, and ROC analyses. The model showed high predictive accuracy, with distinct survival differences between risk groups. Notably, CD38, traditionally seen as protective, was paradoxically associated with poor prognosis in LUAD, a finding supported by immunohistochemistry and immunofluorescence data. GSEA revealed that high-risk genes are enriched in metabolic pathways, while low-risk genes align with immune-related pathways, suggesting better immunotherapy response in the latter group. Conclusions This study presented a novel prognostic protein model for LUAD, highlighting the CD38 expression paradox and enhancing our understanding of protein roles in lung cancer progression. It offered new clinical tools for prognosis prediction and provided assistance for future lung cancer pathogenesis research.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Yu,

Zheng,

Xia

et al. 2024

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…SCCA is a tumor-specific antigen that was first discovered in the 1970s by Kato and Torigoe from cervical squamous cell carcinoma tissues ( 2 ). It is widely found in the cytoplasm of squamous cell carcinomas, such as the uterus, cervix, lung, head and neck, especially in nonkeratinized cancer cells, in which the content of SCCA is more abundant ( 3 – 6 ). SCCA exists in squamous epithelial cells is involved in the differentiation of squamous epithelium and tumor growth of tumor cells, and is often used in the diagnosis of squamous epithelium-derived carcinoma ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

“…Sun et al. ( 3 ) has shown that SCCA can initially evaluate the radiotherapy effect of lung cancer patients and has a certain predictive effect on prognosis. Yang et al.…”

Section: Introductionmentioning

confidence: 99%

Analysis of influencing factors of serum SCCA elevation in 309 CAP patients with normal CEA,NSE and CYFRA21-1

Wang,

Tang,

Liu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionSquamous cell carcinoma antigen (SCCA) is one of the auxiliary diagnostic indicators of lung squamous cell carcinoma, and an increase in serum SCCA can predict the occurrence of lung squamous cell carcinoma. However, whether SCCA is also elevated in pneumonia patients without malignancy is still not clear. Therefore, we studied influencing factors of elevated serum SCCA in patients with community-acquired pneumonia.MethodsWe retrospectively enrolled 309 patients who were admitted to the Respiratory department with normal serum Carcinoembryonic antigen (CEA), Neuron specific enolase (NSE), and Cytokeratin 19 fragment (CYFRA21-1) level and were diagnosed with community-acquired pneumonia (CAP). The patients’ serum SCCA level, body temperature, age, sex, white blood cell (WBC) count, hypersensitive C-reactive protein (Hs-CRP) level, and serum amyloid A (SAA) were recorded. Logistic regression models were used to analyze the risk factors of SCCA elevation. The dose-response relationship between temperature and risk of SCCA increase was analyzed using Restricted cubic splines (RCS).ResultsOf the 309 patients, 143(46.3%) showed elevated SCCA levels. The logistic regression analysis revealed a significant influence of age and body temperature on elevated SCCA (P<0.05) levels. For every one-year increase in age, the probability of elevated SCCA decreased by 3% [OR=0.97,95%CI:0.95,0.99].For every 1°C increase in body temperature, the risk of elevated SCCA increased by 2.75 times [OR=3.75,95%CI:2.55,5.49].The patients were sorted into quartiles based on body temperature. Compared with patients in the Q1 of body temperature group, patients in the Q3 group were at 7.92 times higher risk [OR=7.92, 95%CI:3.27,19.16].and the risk of elevated SCCA was increased by 22.85 times in the Q4 group [OR=23.85,95%CI:8.38,67.89] after adjusting for age, gender, Hs-CRP, SAA, and WBC. RCS analysis showed there was a linear relationship between temperature index and risk of elevated SCCA.ConclusionIn summary, for CAP patients with normal CEA,NSE and CYFRA21-1 level, age and body temperature are influencing factors of SCCA elevation. Higher body temperature has a strong association with the occurrence of SCCA elevation.

show abstract

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case report

王,

Wu,

Shao

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Although the presence of Kirsten rat sarcoma virus (KRAS) mutations predicts of a lack of benefit from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy for none small cell cancer (NSCLC), it may be more sensitive to programmed combination therapy with cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors + anti-angiogenesis. Recent treatment guidelines and clinical studies related to adenocarcinoma in NSCLC have indicated that in patients with inoperable stage IV lung adenocarcinoma, immune checkpoint inhibitors in combination with anti-angiogenic drugs may exert a synergistic effect and significantly improve the efficacy of near-term treatment, but quantification and long-term follow-up of specific clinical indicators are still lacking. No previous cases of long-term good results with camrelizumab combined with anti-angiogenic agents for KRAS-mutated NSCLC have been described. Methods This manuscript reports a case where patients with advanced NSCLC with pleural effusion and KRAS mutations treated poorly with conventional chemotherapy had long-term (more than 18 months) benefit with immunotherapy combined with an anti-angiogenic inhibitor. In this case, pharmaceutical care of the patient was carried out through therapeutic drug adjustment, compliance, efficacy assessment, and safety evaluation to provide a reference for improving the efficacy and safety of drug therapy in clinical practice. Results As of the last follow-up date (December 2023), overall survival was 27 months and the patient is currently in good general condition with no significant complaints of discomfort. Conclusion ICLs in combination with antiangiogenic therapy may be a therapeutic option for patients with KRAS mutations in advanced non-small cell lung cancer with good persistence.

show abstract

Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapy

Cited by 3 publications

References 20 publications

Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Comprehensive proteomic profiling of lung adenocarcinoma: development and validation of an innovative prognostic model

Analysis of influencing factors of serum SCCA elevation in 309 CAP patients with normal CEA,NSE and CYFRA21-1

An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case report

Contact Info

Product

Resources

About